Dear Sir, Type 1 (insulin-dependent) diabetes is thought to be the result of a chronic autoimmune process [1, 2] which eventually leads to B-cell destruction. The onset of the disease is followed in about 11% of patients by a transitory remission phase, which may be related to preservation of residual insulin secretory capacity [3] . A diet rich in fish oil has antiinflammatory properties as indicated by the suppression of autoimmunity in MRL-lpr mice [4] . It is thus possible that a diet rich in eicosapentaenoic acid (EPA) could modulate the immune response and prevent further B-cell damage in newly-diagnosed Type l diabetes mellitus.
In a pilot study, we have investigated the effect of dietary supplementation with fish-oil on remission of newly-diagnosed Type 1 diabetes mellitus. Remission was defined as a blood glucose value less than 7.8 mmol/l fasting and 11.1 mmol/1 post-prandially (2 h after breakfast), and a normal HbA1 (4.9-7.5%) level in the absence of insulin treatment.
Eight (5 male, 3 female) newly-diagnosed ketosis prone Type 1 diabetic patients, aged between 14 and 38 years (mean 25 years), were recruited within 2 weeks of the onset of diabetes. Following baseline assessment, patients were randomly assigned to a standard diabetic diet supplemented either with 20 g MaxEPA (Markfleet Refining Company, Hull, UK) daily, in the form of 20 ml oil, equivalent to 3.6 g EPA, 2.4 g docosahexaenoic acid and 180 kcal (4 patients) or with an isocaloric amount of olive oil (4 patients). All patients were treated with a mixture of soluble and intermediate acting insulins twice daily. Further assessments were made at 1 month and then every 3 months up to 9 months. Diabetic control was assessed by home blood glucose profile and HbA1 levels. Dietary compliance was checked by a dietician at each visit. Heparinised blood was taken for isolation of monocytes, lymphocytes and neutrophils as previously described [5] . Lymphocytes were used for measurement of HLA-DR, interleukin 2 (IL-2), islet cell antibodies (ICA) and complement-fixing islet cell antibodies (CF-ICA). Monocytes and neutrophils were used for analysis of membrane phospholipids [5] .
Diabetic control improved similarly in both groups after the initiation of therapy, but it was not possible to withdraw insulin in any patient (Table 1) . Cholesterol levels fell by 5% and triglyceride by 22% approximately in the experimental group with similar changes were seen in the control group. Platelet counts decreased in the experimental group only by 15% over the course of the study.
Membrane phospholipid analysis of monocytes and neutrophils showed an approximately ten-fold increase in EPA from 0.35% total Short-term dietary supplementation with MaxEPA has been reported to induce either a deterioration or no change in glycaemic control and insulin requirement in Type 1 diabetic patients of some duration [6, 7] . A hypercholesterolaemic effect has been noted by some authors [7] . In Type2 (non-insulin-dependent) diabetic patients MaxEPA has been shown to improve insulin sensitivity by some workers [8] but other authors have found a worsening of metabolic control [6, 91 . The findings of the present study suggest that long-term supplementation of a diabetic diet with MaxEPA does not affect the autoimmune process of newly-diagnosed Type 1 diabetes meUitus.
Yours sincerely, T. Tariq, C. Close, P,. Dodds, G.C. Viberti, T. Lee and D. Vergani
